Actively Recruiting
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
Led by Henan University of Traditional Chinese Medicine · Updated on 2024-09-25
100
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the clinical efficacy of Lifei Xiaoji Wan for advanced non-small cell lung cancer (NSCLC), establish the treatment scheme, and obtain high-quality clinical evidence.
CONDITIONS
Official Title
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of NSCLC
- Tumor stage (TNM) stage is from III to IV
- Age between 18 and 80 years
- Expected survival period greater than 3 months
You will not qualify if you...
- Early-stage patients with prior surgery and no recurrence
- Serious dysfunction of the heart, liver, kidney, or other important organs
- Mental illness or inability to complete the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou, Henan, China, 450000
Actively Recruiting
Research Team
Y
Yuanyuan Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here